Synovial Sarcoma — Trials

Synovial Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

94 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 22
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: USWM CT, LLC
Termination share: 45.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (18)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03520959	A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	terminated	Phase 3	1	Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY	2	Apr 16, 2020	clinicaltrials

Data updated 22 days agoSource updated Apr 16, 2020source: clinicaltrials